Sage Journals: Discover world-class research

Abstract

Objective:

Rhenium-188-HEDP is an effective radiopharmaceutical for the treatment of painful bone metastases from prostate cancer. The effectiveness of the β-radiation emitted by ¹⁸⁸Re might be enhanced by combination with chemotherapy, using the radiosensitization concept. Therefore, the authors investigated the combined treatment of the taxanes, docetaxel and cabazitaxel, with ¹⁸⁸Re in prostate carcinoma cell lines.

Materials and Methods:

The cytotoxic effects of single and combined treatment with taxanes and ¹⁸⁸Re were investigated in three human prostate carcinoma cell lines (PC-3, DU 145, and LNCaP), using the colony-forming assay. The half maximal effective concentration (EC50) of all individual agents was determined. The combined treatment was studied at 0.25, 0.5, 1, 2, and 4 times the EC50 of each agent. The interaction was investigated with a regression model.

Results:

The survival curves showed dose-dependent cell growth inhibition for both the taxanes and ¹⁸⁸Re. The regression model showed a good capability of explaining the data. It proved additivity in all combination experiments and confirmed a general trend to a slight subadditive effect.

Conclusions:

This proof-of-mechanism study exploring radiosensitization by combining ¹⁸⁸Re and taxanes showed no synergism, but significant additivity. This encourages the design of in vivo studies. Future research should explore the potential added value of concomitant treatment of bone metastases with chemotherapy and ¹⁸⁸Re-HEDP.

Get full access to this article

View all access options for this article.

References

Coleman

. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res, 2006; 12:6243s.

Lipton

. Implications of bone metastases and the benefits of bone-targeted therapy. Semin Oncol, 2010; 37:S15.

DePuy

, Anstrom

, Castel

, et al. Effects of skeletal morbidities on longitudinal patient-reported outcomes and survival in patients with metastatic prostate cancer. Support Care Cancer, 2007; 15:869.

Nørgaard

, Jensen

AØ

, Jacobsen

, et al. Skeletal related events, bone metastasis and survival of prostate cancer: A population based cohort study in Denmark (1999 to 2007). J Urol, 2010; 184:162.

Benyamin

, Trescot

, Datta

, et al. Opioid complications and side effects. Pain Physician, 2008; 11:S105.

Finlay

, Mason

, Shelley

. Radioisotopes for the palliation of metastatic bone cancer: A systematic review. Lancet Oncol, 2005; 6:392.

Liepe

, Kotzerke

. Internal radiotherapy of painful bone metastases. Methods, 2011; 55:258.

van Dodewaard-de Jong

, Oprea-Lager

, Hooft

, et al. Radiopharmaceuticals for palliation of bone pain in patients with castration-resistant prostate cancer metastatic to bone: A systematic review. Eur Urol, 2016; 70:416.

Herscher

, Cook

, Pacelli

, et al. Principles of chemoradiation: Theoretical and practical considerations. Oncology (Williston Park), 1999; 13:11.

10.

Bindhu

, Anupama

. Radiosensitization: The new dogma in cancer treatment. Austral Asian J Cancer, 2005; 4:241.

11.

Bentzen

, Harari

, Bernier

. Exploitable mechanisms for combining drugs with radiation: Concepts, achievements and future directions. Nat Clin Pract Oncol, 2007; 4:172.

12.

Palacios

, Miyake

, Rosser

. Radiosensitization in prostate cancer: Mechanisms and targets. BMC Urol, 2013; 13:4.

13.

Ghotra

VPS

, Geldof

, Danen

EHJ

. Targeted radiosensitization in prostate cancer. Curr Pharm Des, 2013; 19:2819.

14.

Alcorn

, Walker

, Gandhi

, et al. Molecularly targeted agents as radiosensitizers in cancer therapy-focus on prostate cancer. Int J Mol Sci, 2013; 14:14800.

15.

Maier

, Hartmann

, Wenz

, et al. Cellular pathways in response to ionizing radiation and their targetability for tumor radiosensitization. Int J Mol Sci, 2016; 17:102.

16.

Steel

, Peckham

. Exploitable mechanisms in combined radiotherapy-chemotherapy: The concept of additivity. Int J Radiat Oncol Biol Phys, 1979; 5:85.

17.

Seiwert

, Salama

, Vokes

. The chemoradiation paradigm in head and neck cancer. Nat Clin Pract Oncol, 2007; 4:156.

18.

O'Rourke

, Roque I Figuls

, et al. Concurrent chemoradiotherapy in non-small cell lung cancer. Cochrane database Syst Rev, 2010:CD002140.

19.

Palmedo

, Manka-Waluch

, Albers

, et al. Repeated bone-targeted therapy for hormone-refractory prostate carcinoma: Randomized phase II trial with the new, high-energy radiopharmaceutical rhenium-188 hydroxyethylidenediphosphonate. J Clin Oncol, 2003; 21:2869.

20.

Biersack

H-J

, Palmedo

, Andris

, et al. Palliation and survival after repeated (188)Re-HEDP therapy of hormone-refractory bone metastases of prostate cancer: A retrospective analysis. J Nucl Med, 2011; 52:1721.

21.

Lange

, Overbeek

, de Klerk

JMH

, et al. Treatment of painful bone metastases in prostate and breast cancer patients with the therapeutic radiopharmaceutical rhenium-188-HEDP. Clinical benefit in a real-world study. Nuklearmedizin, 2016; 55.

22.

Tannock

, de Wit

, Berry

, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med, 2004; 351:1502.

23.

de Bono

, Oudard

, Ozguroglu

, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: A randomised open-label trial. Lancet, 2010; 376:1147.

24.

Kumar

. A new paradigm for the treatment of high-risk prostate cancer: Radiosensitization with docetaxel. Rev Urol, 2003; 5:S71.

25.

Golden

, Formenti

, Schiff

. Taxanes as radiosensitizers. Anticancer Drugs, 2014; 25:502.

26.

Balkman

, Gieger

, Zgola

, et al. In vitro characterization of docetaxel as a radiosensitizer in canine and feline cancer cell lines. Open J Vet Med, 2012; 2:285.

27.

van Bokhoven

, Varella-Garcia

, Korch

, et al. Molecular characterization of human prostate carcinoma cell lines. Prostate, 2003; 57:205.

28.

Harrington

, Billingham

, Brunner

, et al. Guidelines for preclinical and early phase clinical assessment of novel radiosensitisers. Br J Cancer, 2011; 105:628.

29.

Franken

NAP

, Rodermond

, Stap

, et al. Clonogenic assay of cells in vitro. Nat Protoc, 2006; 1:2315.

30.

Oprea-Lager

, van Kanten

, van Moorselaar

RJA

, et al. [18F]fluoromethylcholine as a chemotherapy response read-out in prostate cancer cells. Mol Imaging Biol, 2015; 17:319.

31.

Chou

T-C

, Talalay

. Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul, 1984; 22:27.

32.

Chou

. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev, 2006; 58:621.

33.

Tallarida

. An overview of drug combination analysis with isobolograms. J Pharmacol Exp Ther, 2006; 319:1.

34.

Oprea-Lager

, Bijnsdorp

, Van Moorselaar

RJA

, et al. ABCC4 decreases docetaxel and not cabazitaxel efficacy in prostate cancer cells in vitro. Anticancer Res, 2013; 33:387.

35.

Geldof

, de Rooij

, Versteegh

, et al. Combination 186Re-HEDP and cisplatin supra-additive treatment effects in prostate cancer cells. J Nucl Med, 1999; 40:667.

36.

Greco

, Bravo

, Parsons

. The search for synergy: A critical review from a response surface perspective. Pharmacol Rev, 1995; 47:332.

37.

Hennessey

, Rosner

, Bast

Jr , et al. A bayesian approach to dose–response assessment and synergy and its application to in vitro dose–response studies. Biometrics, 2010; 66:1275.

38.

Twigger

, Vidal

, White

, et al. Enhanced in vitro and in vivo cytotoxicity of combined reovirus and radiotherapy. Clin Cancer Res, 2008; 14:912.

39.

van Dodewaard-de Jong

, de Klerk

JMH

, Bloemendal

, et al. A phase I study of combined docetaxel and repeated high activity 186Re-HEDP in castration-resistant prostate cancer (CRPC) metastatic to bone (the TAXIUM trial). Eur J Nucl Med Mol Imaging, 2011; 38:1990.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.03 MB

0.02 MB

0.07 MB

Cytotoxic Effects of the Therapeutic Radionuclide Rhenium-188 Combined with Taxanes in Human Prostate Carcinoma Cell Lines